skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: In vivo mutagenicity and clastogenicity of ionizing radiation in nuclear medicine

Abstract

The overall goal of our research remains to investigate the mutagenic and clastogenic effects of exposure to low levels of ionizing radiation to human lymphocytes. We are utilizing these endpoints to examine sets of individuals who have been exposed to ionizing radiation as a result of medical procedures. The cohorts we are studying include: nuclear medicine technicians, two set of nuclear medicine patients, sets of controls and a new set of Hodgkins disease patients. Emphasis in the second year has been on measurements of chromosome aberrations in patients imaged with thallium-201, mutant frequencies in patients imaged with technetium-99, mutant frequencies in nuclear medicine technicians and physical therapists, and mutant frequencies in patients treated for Hodgkins disease with radiotherapy. The progress in these areas is described in this report in more detail.

Authors:
Publication Date:
Research Org.:
Harvard Univ., Boston, MA (USA). School of Public Health
Sponsoring Org.:
DOE/ER
OSTI Identifier:
6217102
Report Number(s):
DOE/ER/60745-3
ON: DE91005587
DOE Contract Number:
FG02-89ER60745
Resource Type:
Technical Report
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; CHROMOSOMAL ABERRATIONS; RADIOINDUCTION; GENE MUTATIONS; LYMPHOCYTES; BIOLOGICAL RADIATION EFFECTS; TECHNETIUM 99; DIAGNOSTIC USES; THALLIUM 201; IMAGE PROCESSING; IONIZING RADIATIONS; MUTAGENESIS; NUCLEAR MEDICINE; PATIENTS; PROGRESS REPORT; RADIATION INDUCED MUTANTS; TRACER TECHNIQUES; ANIMAL CELLS; BETA DECAY RADIOISOTOPES; BETA-MINUS DECAY RADIOISOTOPES; BIOLOGICAL EFFECTS; BIOLOGICAL MATERIALS; BLOOD; BLOOD CELLS; BODY FLUIDS; CONNECTIVE TISSUE CELLS; DAYS LIVING RADIOISOTOPES; DOCUMENT TYPES; ELECTRON CAPTURE RADIOISOTOPES; HEAVY NUCLEI; HOURS LIVING RADIOISOTOPES; INTERMEDIATE MASS NUCLEI; ISOMERIC TRANSITION ISOTOPES; ISOTOPE APPLICATIONS; ISOTOPES; LEUKOCYTES; MATERIALS; MEDICINE; MUTANTS; MUTATIONS; NUCLEI; ODD-EVEN NUCLEI; PROCESSING; RADIATION EFFECTS; RADIATIONS; RADIOISOTOPES; SECONDS LIVING RADIOISOTOPES; SOMATIC CELLS; TECHNETIUM ISOTOPES; THALLIUM ISOTOPES; USES; YEARS LIVING RADIOISOTOPES; 550601* - Medicine- Unsealed Radionuclides in Diagnostics

Citation Formats

None, None. In vivo mutagenicity and clastogenicity of ionizing radiation in nuclear medicine. United States: N. p., 1990. Web. doi:10.2172/6217102.
None, None. In vivo mutagenicity and clastogenicity of ionizing radiation in nuclear medicine. United States. doi:10.2172/6217102.
None, None. Mon . "In vivo mutagenicity and clastogenicity of ionizing radiation in nuclear medicine". United States. doi:10.2172/6217102. https://www.osti.gov/servlets/purl/6217102.
@article{osti_6217102,
title = {In vivo mutagenicity and clastogenicity of ionizing radiation in nuclear medicine},
author = {None, None},
abstractNote = {The overall goal of our research remains to investigate the mutagenic and clastogenic effects of exposure to low levels of ionizing radiation to human lymphocytes. We are utilizing these endpoints to examine sets of individuals who have been exposed to ionizing radiation as a result of medical procedures. The cohorts we are studying include: nuclear medicine technicians, two set of nuclear medicine patients, sets of controls and a new set of Hodgkins disease patients. Emphasis in the second year has been on measurements of chromosome aberrations in patients imaged with thallium-201, mutant frequencies in patients imaged with technetium-99, mutant frequencies in nuclear medicine technicians and physical therapists, and mutant frequencies in patients treated for Hodgkins disease with radiotherapy. The progress in these areas is described in this report in more detail.},
doi = {10.2172/6217102},
journal = {},
number = ,
volume = ,
place = {United States},
year = {Mon Jan 01 00:00:00 EST 1990},
month = {Mon Jan 01 00:00:00 EST 1990}
}

Technical Report:

Save / Share:
  • The overall goals of our research remains to investigate the mutagenic and clastogenic effects of exposure to low levels of ionizing radiation in human lymphocytes. We are studying hospital patients referred to a nuclear medicine department for diagnostic cardiac imaging and nuclear medicine technologists who administer radionuclides.
  • The overall goal of our research was to investigate the mutagenic and clastogenic effects of exposure to low levels of ionizing radiation to human lymphocytes. Principally, we studied hospital patients referred to a nuclear medicine department for diagnostic cardiac imaging and nuclear medicine technologists who administer radionuclides. Emphasis in the first year, as described in the first progress report, was on optimization of the hprt mutation assay, measurement of mutant frequencies in patients imaged with thallium-201, and measurement of mutant frequencies in controls. Emphasis in the second and third years was on measurements of: (1) chromosome aberrations in patients imagedmore » with thallium-201; (2) mutant frequencies in patients imaged with technetium-99; (3) mutant frequencies in nuclear medicine technicians and physical therapists; and (4) mutant frequencies in patients treated for Hodgkins disease with radiotherapy. The completed work has been published and is described below in more detail.« less
  • The overall goal of our research remains to investigate the mutagenic and clastogenic effects of exposure to low levels of ionizing radiation to human lymphocytes. Principally, we are studying hospital patients referred to a nuclear medicine department for diagnostic cardiac imaging and nuclear medicine technologies who administer radionuclides. Emphasis in the first year, as described in the first progress report, was on optimization of the hprt mutation assay, measurement of mutant frequencies in patients imaged with thallium-201, and measurement of mutant frequencies in controls. Emphasis in the second year has been on measurements of (1) chromosome aberrations in patients imagedmore » with thallium-201, (2) mutant frequencies in patients imaged with technetium-99, (3) mutant frequencies in nuclear medicine technicians and physical therapists, (4) mutant frequencies in patients treated for Hodgkins disease with radiotherapy. The progress in these areas is described.« less
  • The overall goal of our research was to investigate the mutagenic and clastogenic effects of exposure to low levels of ionizing radiation to human lymphocytes. Principally, we studied hospital patients referred to a nuclear medicine department for diagnostic cardiac imaging and nuclear medicine technologists who administer radionuclides. Emphasis in the first year, as described in the first progress report, was on optimization of the hprt mutation assay, measurement of mutant frequencies in patients imaged with thallium-201, and measurement of mutant frequencies in controls. Emphasis in the second and third years was on measurements of: (1) chromosome aberrations in patients imagedmore » with thallium-201; (2) mutant frequencies in patients imaged with technetium-99; (3) mutant frequencies in nuclear medicine technicians and physical therapists; and (4) mutant frequencies in patients treated for Hodgkins disease with radiotherapy. The completed work has been published and is described below in more detail.« less
  • The overall goals of our research remains to investigate the mutagenic and clastogenic effects of exposure to low levels of ionizing radiation in human lymphocytes. We are studying hospital patients referred to a nuclear medicine department for diagnostic cardiac imaging and nuclear medicine technologists who administer radionuclides.